Helga Zharov

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics engages in a biopharmaceuticals company. It provides research services with focus on human genes. The company was founded by K?ri Stef?nsson in August 1996 and is headquartered in Reykjavik, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics engages in a biopharmaceuticals company. It provides research services with focus on human genes. The company was founded by K?ri Stef?nsson in August 1996 and is headquartered in Reykjavik, Iceland.

deCODE genetics engages in a biopharmaceuticals company. It provides research services with focus on human genes. The company was founded by K?ri Stef?nsson in August 1996 and is headquartered in Reykjavik, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Virding hf provides financial services. It operates through four segments: Asset Management, Capital Markets, Corporate Finance and Private Equity Funds. The Asset Management segment offers asset management services that are tailored to the needs of high net worth individuals, pension funds, NGOs and institutional investors. The segment also offers independent advice and personal assistance. The Capital Markets segment works as intermediaries for investments in a wide variety of asset classes for Iceland´s largest investors and international clients such as corporate, institutional investors, UCITS, pension funds, public entities and other professional investors. The Corporate Finance segment offers its clients a wide range of advisory services including fund raising, corporate and financial restructuring, M&A and company divestitures. The Private Equity Funds segment invests in small to medium-size Icelandic companies with a strong market position and attractive growth potential. The company was founded in 1999 and is headquartered in Reykjavík, Iceland.

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.